Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01577173 · ClinicalTrials.gov registry record · Phase 2

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

A Phase 2 study of Head and Neck Cancer, sponsored by Genentech.

Completed
Registry status
Phase 2
Development phase
122
Enrollment target
20
Study locations

NCT01577173: Completed Phase 2 study of Head and Neck Cancer, sponsored by Genentech.

NCT01577173 is a Phase 2 study of Head and Neck Cancer that has completed, run by Genentech. The registered enrollment target is 122 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01577173, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 2
Development phase
122 participants
Enrollment target
20
Study locations

Study Summary

This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or following platinum-based chemotherapy. Patients will be randomized to receive either MEHD7945A 1100 mg intravenously (iv) every 2 weeks or cetuximab 400 mg/m2 iv loading dose followed by 250 mg/m2 iv weekly. Patients treated with cetuximab (Arm B) may cross-over to MEHD7945A (Arm A) upon central confirmation of progressive disease and upon meeting eligibility criteria. Anticipated time on study treatment is until disease progression or intolerable toxicity occurs.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG cetuximab
  • DRUG MEHD7945A

Study Locations (20)

New South Wales

  • - Darlinghurst
  • - Waratah
  • - Wollongong

Massachusetts

  • - Boston
  • - Boston

California

  • - Stanford

Colorado

  • - Aurora

Florida

  • - Miami

Illinois

  • - Chicago

Kentucky

  • - Paducah

Maryland

  • - Baltimore

Trial Details

FieldValue
Enrollment Target 122 participants
Start Date 2012-07
Est. Completion 2015-06
Phase Phase 2
Genentech

332 total trials

What the finished NCT01577173 record still lists

NCT01577173 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (53% lower).

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which cetuximab is the first listed.

NCT01577173 names 20 study sites across 17 states, led by New South Wales, Massachusetts, California.

Frequently Asked Questions

What is clinical trial NCT01577173 about?

NCT01577173 is a clinical study titled "A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck". This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or following platinum-based chemotherapy. Patients will be randomized to recei...

What is the current status of trial NCT01577173?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2012-07. Estimated completion is 2015-06.

What conditions does trial NCT01577173 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT01577173?

The interventions under investigation include: cetuximab (DRUG), MEHD7945A (DRUG).

Who is sponsoring clinical trial NCT01577173?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01577173 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01577173's enrollment target sits among peer trials

122 72nd of 250 higher than 179 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03363373 · 122 participants · Phase 2

    Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

  • NCT03463954 · 122 participants · NA

    Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

  • NCT04503265 · 122 participants · Phase 1

    A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

  • NCT04700527 · 122 participants · Phase 1

    The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01577173, the US trial registry maintained by the National Library of Medicine. NCT01577173 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.